The offering is large (~12% dilution) but was oversubscribed by leading healthcare investors and extends runway into 2029, removing near-term financing overhang. The Sanofi milestone and positive REC-4881/REC-1245 data provide pipeline validation. Monitor FDA discussions for REC-4881 registrational trial initiation (targeted 2H 2027) and additional REC-1245 expansion data (2H 2027). The Q2 revenue decline (-60% YoY) reflects lumpy collaboration revenue, not business deterioration.
Price Chart
Executive Summary
Recursion Pharmaceuticals filed an 8-K announcing a $200M oversubscribed follow-on offering of 61.54M shares at $3.25/share, alongside positive clinical data updates (REC-4881 FAP data showing 47% median polyp reduction, REC-1245 partial responses in endometrial cancer) and a Sanofi milestone ($10M payment for optioned immunology development candidate). The offering extends cash runway into 2029 but causes ~12% dilution from the ~532M pre-offering share base. The prior quarter (Q2 2026) showed revenue of $7.7M (down 60% YoY from $19.2M) and a net loss of $131M (EPS -$0.25 vs consensus -$0.23, a miss).
Key Financial Metrics
Key Facts
- Priced underwritten offering of 61,540,000 shares at $3.25/share for ~$200M gross proceeds
- Purchase price to underwriters is $3.055/share; offering expected to close Oct 16, 2026
- Sanofi optioned first development candidate from collaboration, triggering $10M milestone payment; total milestone payments from Sanofi now $144M
- REC-4881 Phase 1b/2 TUPELO study: 47% median total polyp burden reduction at week 13; 55% median reduction in upper GI; 85% maintained reductions below baseline after 12 weeks off treatment
- REC-1245 Phase 1 DAHLIA study: 2 confirmed partial responses in endometrial cancer, 1 unconfirmed in HCC; 91.7% disease control rate at ≥45 mg doses
- Preliminary cash balance ~$561M as of Sep 30, 2026; cash runway extended into 2029 with offering proceeds
- Q2 2026 revenue $7.7M (down 60% YoY from $19.2M); net loss $131M; EPS -$0.25 vs consensus -$0.23 (miss)
- Cash operating expense guidance lowered to $375M for FY2026 (from $390M)
- 61.54M new shares represent ~11.6% dilution vs ~532M pre-offering weighted-average shares
Financial Impact
$200M gross proceeds from offering; ~12% dilution; $10M Sanofi milestone; cash runway extended into 2029
Risk Factors
- Dilution of ~12% from 61.54M new shares may pressure near-term stock price
- REC-4881 registrational trial design and FDA alignment not yet finalized; pivotal trial initiation targeted for 2H 2027
- Revenue heavily dependent on collaboration milestones; Q2 revenue declined 60% YoY
- Net loss of $131M in Q2 2026; company remains pre-revenue from product sales
- REC-1245 data is early (12 efficacy-evaluable patients); durability and expansion results may differ
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001601830-26-000128 |
| Exhibit: exhibit992-businessupdate.htm | 0001601830-26-000128 |
| Exhibit: exhibit991-sanofipr.htm | 0001601830-26-000128 |
| Exhibit: exhibit51opinionofcounsel.htm | 0001601830-26-000128 |
| Exhibit: exhibit994-pricingpr.htm | 0001601830-26-000128 |
| Document: 0001601830-26-000128-index-headers.html | 0001601830-26-000128 |
| Document: 0001601830-26-000128-index.html | 0001601830-26-000128 |
| Document: 0001601830-26-000128.txt | 0001601830-26-000128 |
| 8-K Data (Synthetic) | 0001601830-26-000128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 424B5 | $3.47 $3.58 | ▼ −3.32% | ▼ −3.23% | $3.80 (−9.67%) |
Oct 15, 2026 11d ago | 8-K | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $3.80 (−8.65%) |
Oct 15, 2026 11d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $3.80 (−8.65%) |
Oct 15, 2026 11d ago | Press Release | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $3.80 (+8.65%) |
Oct 15, 2026 11d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $3.80 (−8.65%) |
Oct 15, 2026 11d ago | 424B5 | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $3.80 (+8.65%) |
Oct 6, 2026 20d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $3.80 (−17.93%) |
Oct 6, 2026 20d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $3.80 (−17.93%) |
Sep 21, 2026 5w ago | 8-K | $3.97 $3.70 | ▼ −6.80% | ▼ −5.78% | $3.80 (−4.28%) |
Sep 10, 2026 6w ago | Insider Cluster | $3.20 $3.83 | ▲ +19.69% | ▲ +20.03% | $3.80 (+18.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers